Modified Probiotics Could Improve Heart Health

636096130891644595^8EB207C0DC88C7558DE73FF3ABE5A4807F0CA904C39BA92345^pimgpsh_fullsize_distr.jpg

16 Sep 2016 --- A new study has shown how a genetically modified strain of the probiotic Lactobacillus could lower blood pressure, improve heart contractility, and reduce heart wall thickness. The study was presented at the American Heart Association’s Council on Hypertension 2016 Scientific Sessions.

High blood pressure in the lungs is known as pulmonary hypertension, and results in the heart having to work harder to pump blood from the heart through the arteries of the lungs, putting added strain on the heart. Risk factors for pulmonary hypertension include family history, congenital heart defects, cocaine use, and chronic lung disease.

The animal study saw researchers give an oral, genetically modified strain of the probiotic Lactobacillus to rats with high blood pressure in the lungs. The results showed reduced blood pressure, improved heart contractility, and reduced heart wall thickness.

“It is known that the peptide Angiotensin-(1-7), or Ang-(1-7), is beneficial for the treatment of pulmonary hypertension in animal experiments, but taking this peptide orally hasn’t been effective because it’s easily degraded in the stomach,” said Colleen Cole Jeffrey, M.S., study author and graduate research assistant in the department of Physiology and Functional Genomics at the University of Florida in Gainesville.

“To overcome this obstacle, we genetically engineered strains of Lactobacillus, a probiotic bacteria, to express and secrete Ang-(1-7). And in an animal study, we tested whether oral feeding of these modified bacteria would effectively treat pulmonary hypertension.”

Researchers measured the thickness of the rat heart wall and the ability of the heart to contract, as well as the systolic blood pressure in the right side of the heart, which is a marker for pulmonary hypertension.

“All the animals with pulmonary hypertension had elevated blood pressure, increased heart wall thickness, and decreased cardiac contractility compared to normal animals,” Cole Jeffrey said.

“However, the group of pulmonary hypertensive animals that were fed with the Ang-(1-7) probiotic had a 43 percent reduction in blood pressure, a 33 percent reduction in heart wall thickness, and a significant improvement in heart contractility, compared to the untreated animals with pulmonary hypertension.”

Although these findings are experimental, they suggest that probiotics can be modified for oral delivery of beneficial peptides such as Ang-(1-7), and consumption of these modified probiotics may treat pulmonary hypertension and associated right heart dysfunction.

“Certainly, there is still much more work to be done,” said Mohan Raizada, Ph.D., principal investigator of the study. “But if our animal data holds true in clinical trials, probiotic consumption, as well as the use of genetically-modified probiotics, may emerge as a novel therapeutic approach for pulmonary hypertension therapy – either as standalone treatment or in conjunction with other medical therapies.”

Related Articles

Business News

Lakeview Equity invests in nutritional solutions provider NutriScience Innovations

11 Dec 2017 --- Lakeview Equity Partners, LLC, a US$40 million Milwaukee, US-based private equity fund, has invested in NutriScience Innovations, LLC, based in Trumbull, Connecticut, US. NutriScience is a cGMP-certified global supplier of nutritional and functional ingredients to companies that manufacture nutraceutical, pharmaceutical, food and beverage, and dietary products.

Business News

New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

Business News

Weight management program can put Type 2 diabetes into remission finds Lancet study

06 Dec 2017 --- Type 2 diabetes can be reversed following an intensive weight management program, according to a randomized trial in adults who have had the condition for up to six years, published in The Lancet. The findings lend support to the widespread use of this type of intervention in the routine care of Type 2 diabetes across health services.

Business News

Kappa Bioscience reveals free vitamin K2 MK-7 quality testing program

06 Dec 2017 --- Kappa Bioscience has announced the worldwide launch of a free vitamin K2 MK-7 quality testing program. The program, announced at CPhI India, is open to finished K2 products, from any source, for testing and verification of the product’s K2 label claim. The program supports wider goals of educating markets about K2 stability and advancing K2 science to resolve the question of why unprotected K2 is unstable in mineral formulations. 

Business News

Nestle acquires Atrium for US$2.3 billion, extends consumer healthcare portfolio

06 Dec 2017 --- Nestle has agreed to acquire Canadian nutritional health products manufacturer Atrium Innovations from a group of investors led by Permira Funds for US$2.3 billion in cash. Nestle notes that the move for the company, whose 2017 sales are expected to reach almost US$700 million, supports Nestle’s pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories.

More Articles
URL : http://www.nutritioninsight.com:80/news/modified-probiotics-could-improve-heart-health.html